About
Experts
Webinars & Conferences
Webinars
Conference recordings
External Webinars
Antimicrobial Viewpoints
Resources
Library
Antimicrobial Encyclopaedia
Conference calendar
JOIN US
Log in
Lost your password?
Create your account
My account
Logout
You are here
:
Home
-
Phase 3
Advanced search
Search our library
Use the filters below to narrow your search:
Content format
Article
Definition
Encyclopaedia
External resource
Video
Resource type
Antimicrobial Viewpoint
Conference
Database
Funding Mechanism
Guideline
Organization
Presentation
Project
Protocol/SOP
Publication
Scientific Journal
Tool
Video
Webinar
Drug development
CMC
Discovery
Exploratory
Hit-to-lead
Lead-to-candidate
Phase 1
Phase 2
Phase 3
Phase 4
PK/PD
Preclinical development
Regulatory
Screening
Toxicology
Indication
ABSSI
Bloodstream infection
Gonorrhoea
HAP/VAP
IAI
Pneumonia
SSTI
STI
Tuberculosis
UTI
Microbe / Microbial properties
Acinetobacter baumannii
Enterobacteriaceae
Enterococcus faecium
Escherichia coli
ESKAPE
Gram negative
Gram positive
Klebsiella pneumoniae
MDR
PDR
Pseudomonas aeruginosa
Staphylococcus aureus
WHO priority pathogens
XDR
Antibiotics class
Aminoglycosides
Carbapenems
Cephalosporins
Diarylquinolines
Glycopeptides
Lincomycins
Macrolides
Penicillins
Quinolones
Sulfonamides
Tetracyclines
Other tags
Access
Diagnostics
Stewardship
Search
Antimicrobial Resistance Solutions
Antimicrobial Chemotherapy Conference 2019
Clinical Microbiology for a Development Program
European Commission: Funding opportunities
Target product profiles for needed antibacterial agents: enteric fever, gonorrhoea, neonatal sepsis, urinary tract infections and meeting report
European Committee on Antimicrobial Susceptibility Testing – EUCAST
Clinical & Laboratory Standards Institute: CLSI Guidelines
Tackling the drug-resistance pandemic – 2020 and beyond
Running a phase 3 trial for a new drug for gonorrhoea during the coronavirus pandemic
Why we need to prioritize developing antibiotics for children
A new cephalosporin has been approved
Journey towards a better antimicrobial pipeline; is there light at the end of the tunnel?
Recent approvals – do they make a difference?
Developing antibiotics for children – medical need and regulatory challenges
Building better breakpoints: data and methods needed to determine breakpoints for new agents
Putting children first in the fight against antibiotic resistance
GARDP: Bringing new treatments for drug-resistant infections to all who need them
Non-traditional antibacterial therapeutic options and challenges
Clinical development for non-developers Part 3: Antibacterial Drug Enhancer Combinations and Non-traditional Products
Clinical development for non-developers, part 2: Development of antibacterial drugs targeting specific pathogens
PK-PD in support of accelerated programmes for antimicrobial development: how much is enough?
Antibacterial drugs: Clinical development for non-developers Part 1: Traditional development – tiers A and B
Adaptive trial
Phase 1, 2, 3, 4 trials
Clinical Development
Minimum inhibitory concentration (MIC)
Investigational new drug (IND)
Breakpoint concentration, clinical
Pharmacokinetics-pharmacodynamics (PK/PD)
Superiority trial
Plasma concentration
Therapeutic window
Target product profile (TPP)
Standard of care (SOC)
Sepsis
Randomized clinical trial (RCT)
Pro-drug
Placebo-controlled trial
Non-inferiority margin
Drug product, medicinal product
Cmax
Antimicrobial susceptibility testing (AST), resistance testing
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Marketing authorization application (MAA)
Limited population pathway for antimicrobial and antifungal drugs (LPAD)
Non-inferiority trial
Active pharmaceutical ingredient (API)
We use cookies to improve your experience with our website. By continuing to browse our website, you are agreeing to our use of cookies. However, you can change your cookie settings at any time in your browser.
Read our
cookie policy